durvalumab
AstraZeneca halts lung cancer trials amidst safety concerns
October 13, 2015Manufacturing and Production AZD9291, AstraZeneca, MEDI4736, NSCLC, drug safety, durvalumab, interstitial lung disease, lung cancer, non-small cell lung cancer
AstraZeneca is stopping two trials of a combination of two of its pipeline cancer treatments, after reports that the pairing …
AstraZeneca and Peregrine in immuno-oncology collaboration
August 24, 2015Research and Development AstraZeneca, Cancer, MEDI4736, Peregrine, Peregrine Pharmaceuticals, bavituximab, durvalumab, immunoncology, immunotherapy, oncology, tumours
AstraZeneca and Peregrine Pharmaceuticals will collaborate on a clinical trial to test two of the companies’ cancer treatments. The Phase …
MedImmune and Mirati to partner on lung cancer combo
August 6, 2015Research and Development AstraZeneca, Cancer, MedImmune, Mirati, Mirati Therapeutics, NSCLC, durvalumab, immuno-oncology, immunotherapy, lung cancer, mocetinostat
MedImmune is entering into an exclusive clinical trial collaboration with US-based Mirati Therapeutics to test a novel immuno-oncology combination in …
Latest content
Long-acting therapies set to reshape HIV treatment market
August 21, 2026
MHRA approves Romvimza for tenosynovial giant cell tumour
August 20, 2026
